Clinical Edge Journal Scan

MicroRNAs show promising predictive value for early breast cancer


 

Key clinical point : Differences in microRNAs (mRNAs), a group of small RNAs that regulate gene expression, can be used to distinguish among breast cancer subtypes.

Major finding : Altered expression of microRNAs distinguished between cancer and healthy samples, and also identified breast cancer subtypes including HER2, Luminal A, Luminal B, and triple negative breast cancer, according to a retrospective study of 740 breast cancer cases included in the review.

Study details : The data come from a review of the latest research on the prognostic and predictive value of microRNAs in patients with luminal A breast cancer.

Disclosures: The study was supported by the Scientific Grant Agency of the Ministry of Education of the Slovak Republic, the Slovak Research and Development Agency, and the Operational Programme Research and Innovation funded by the ERDF.

Citation: Kudela E et al. Int J Mol Sci. 2020 Oct 17. doi: 10.3390/ijms21207691.

Recommended Reading

Pembrolizumab approved for triple-negative breast cancer
MDedge Hematology and Oncology
Using telehealth to deliver palliative care to cancer patients
MDedge Hematology and Oncology
Pregnancy outcomes ‘favorable’ after BRCA breast cancer treatment
MDedge Hematology and Oncology
Black women show higher rates of three breast cancer subtypes
MDedge Hematology and Oncology
Immediate breast reconstruction after chemotherapy doesn’t hurt survival
MDedge Hematology and Oncology
Vacuum-assisted biopsy predicts post-treatment residual disease in breast cancer
MDedge Hematology and Oncology
Textured breast implants may raise risk of cancer relapse
MDedge Hematology and Oncology
DNA-based model predicts overall survival in breast cancer
MDedge Hematology and Oncology
Exercise and diet intervention fail to improve fatigue in breast cancer patients on chemotherapy
MDedge Hematology and Oncology
Income loss shows no link to stress levels in young women with breast cancer
MDedge Hematology and Oncology